Oric Pharmaceuticals, Inc.
corporate_fare Company Profile
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 13 items for ORIC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-03, rated 7/10. Across its 13 most recent items scored 7 or higher, the top rating is 8/10, with 10 rated 8 or above. Recent SEC coverage for ORIC spans 10-Q, 8-K, DEF 14A, 424B5.
Recent high-impact activity:
- ORIC Q2 2026: Cash Runway Extended to H2 2028 as Rinzimetostat Phase 3 Launches
- ORIC Launches Phase 3 Trial, Extends Cash Runway to 2H 2028 with $387.6M
- ORIC Initiates Phase 3 Trial for Prostate Cancer Drug, Secures Bayer Supply Deal
- Stockholders Approve Amended Equity Plan with Increased Annual Share Reserve
- ORIC Pharmaceuticals Advances Lead Candidates to Phase 3, Secures $59.9M via ATM, Extends Cash Runway
Financial Snapshot
Short Interest & Short Volume
14.21 days to coverFINRA reported short interest of 17,532,473 shares in ORIC as of the September 15, 2026 settlement, a 1.5% increase from the prior period — about 14.2 days to cover at its recent average daily volume. On October 2, 2026, 37.7% of ORIC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.